Showing 3931-3940 of 8681 results for "".
- Skin Cancer Foundation Names New Executive Directorhttps://practicaldermatology.com/news/skin-cancer-foundation-names-new-executive-director/2470856/The Skin Cancer Foundation (SCF), a national nonprofit organization that is committed to decreasing the incidence and mortality of the world’s most common cancer through public education, announced that it has appointed Becky Kamowitz to the role of executive director. Kamowitz has worked
- Genetic Study Reveals Psoriasis-Sudden Hearing Loss Connectionhttps://practicaldermatology.com/news/genetic-study-reveals-psoriasis-hearing-loss-connection/2470853/A recent genetic study has established a causal relationship between psoriasis and an elevated risk of sudden sensorineural hearing loss (SSNHL). Researchers derived the findings using Mendelian randomization (MR) analysis to identify potential connections between inflammatory skin disease
- Hair Care Market to Reach $20B by 2029: Reporthttps://practicaldermatology.com/news/hair-care-market-reach-20b-2029-report/2470831/The U.S. hair care market is projected to reach $20 billion by 2029, according to a report released by ResearchAndMarkets.com. The report noted that hair care remains resilient despite economic fluctuations due to consumer demand for premium and sustainable products and cited the rising p
- Method Review: A Closer Look at Cryo-EM’s Impact on Dermatologyhttps://practicaldermatology.com/news/method-review-a-closer-look-at-cryo-ems-impact-on-dermatology/2470806/A recent method review in the Journal of Investigative Dermatology points to the potential of cryogenic electron microscopy (cryo-EM) in dermatological research. According to the authors, advanced imaging technology enables atomic-resolution visualization of macromolecules in thei
- Castle Biosciences' Test Identifies AD Patients Likely to Achieve EASI90https://practicaldermatology.com/news/castle-biosciences-test-identifies-ad-patients-likely-achieve-easi90/2470795/Castle Biosciences has announced its investigational gene expression profile test for atopic dermatitis (AD) may identify patients likely to achieve a 90% or greater reduction in Eczema Area and Severity Index (EASI) scores within three months of targeted therapy initiation. Currently, ov
- New Computational System Evaluates Vitiligo Repigmentation Rateshttps://practicaldermatology.com/news/new-computational-system-evaluates-vitiligo-repigmentation-rates/2470766/A research team from Shenzhen People’s Hospital have developed a computational system for evaluating repigmentation rates in vitiligo patients, according to a new paper in the Journal of Investigative Dermatology. The retrospective study, conducted from June 2019 to November 2022
- Extended Analysis Confirms Favorable Safety for Upadacitinibhttps://practicaldermatology.com/news/extended-analysis-confirms-favorable-safety-upadacitinib/2470761/Results from a long-term integrated analysis support the favorable safety profile of upadacitinib for moderate-to-severe atopic dermatitis (AD) in adolescents and adults. The analysis, presented at the recent Revolutionizing Atopic Dermatitis (RAD) Conference, included over 9,000 patient-y
- Arcutis Submits sNDA for Roflumilast for Children 2 to 5 With ADhttps://practicaldermatology.com/news/arcutis-submits-snda-roflumilast-children-2-5-ad/2470667/Arcutis Biotherapeutics, Inc. announced the submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for roflumilast (ZORYVE) cream 0.05%, a once-daily, next-generation phosphodiesterase 4 (PDE4) inhibitor, for the topical treatment of mild-to-moderate
- FDA Approves Tapinarof Cream, 1%, for ADhttps://practicaldermatology.com/news/fda-approves-tapinarof-cream-1-ad/2470664/The US Food and Drug Administration (FDA) approved tapinarof cream, 1%, an aryl hydrocarbon receptor agonist, for an additional indication of the topical treatment of atopic dermatitis (AD) in adults and pediatric patients 2 years of age and older, Organon announced. Organon received the FDA appr
- JAK Inhibitors May Help Eosinophilic Colitis in AD Patientshttps://practicaldermatology.com/news/jak-inhibitors-may-help-eosinophilic-colitis-ad-patients/2468766/Janus kinase (JAK) inhibitors show promise in managing eosinophilic colitis (EoC) in adults with coexisting atopic dermatitis (AD), according to results from a novel case series. Researchers publishing in The Clinical Journal of Gastroenterology presented four cases of adult EoC s